Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057 Meeting Abstract
| Authors: | Balar, A. V.; Kamat, A. M.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J. L.; Bajorin, D. F.; Roumiguié, M.; Singer, E. A.; Krieger, L. E. M.; Grivas, P.; Seo, H. K.; Nishiyama, H.; Konety, B. R.; Nam, K.; Zambon, J. P.; Kapadia, E.; De Wit, R. |
| Abstract Title: | Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057 |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 287s |
| Language: | English |
| ACCESSION: | WOS:000560368302297 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.5041 |
| Notes: | Meeting Abstract: 5041 -- Source: Wos |
